NDASUBCUTANEOUSSOLUTION
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
3/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REDEMPLO (plozasiran) is an APOC-III-directed RNA interaction therapeutic administered as a subcutaneous solution. It represents a novel mechanism targeting apolipoprotein C-III to modulate lipid metabolism. Specific indications and patient population details are not yet publicly disclosed in this dataset.
Launch12.2 years to LOE
Early-stage launch with zero recorded commercial claims suggests nascent market entry; commercial team will scale rapidly pending uptake and indication breadth expansion.
Mechanism of Action
Pharmacologic Class:
APOC-III-directed RNA Interaction
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Started Apr 2025
288 enrolled
Severe Hypertriglyceridemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Started Apr 2025
869 enrolled
Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Started Jul 2024
311 enrolled
Severe Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Started Jul 2024
446 enrolled
Severe Hypertriglyceridemia
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Started May 2024
1,456 enrolled
Hypertriglyceridemia
Worked on REDEMPLO at Arrowhead Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.